Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2025 07:42 ET | Source: Research and Markets

L-Ornithine L-Aspartate Market Review and Forecast to 2030, Featuring Profiles of Key Players - Evonik, Kyowa Hakko, Synova Biotech, and Haitian Amino Acid

Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "L-Ornithine L-Aspartate Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application" report has...
April 11, 2024 11:06 ET | Source: Research and Markets

Cirrhosis Market and Pipeline Insights, 2024: Analysis of Emerging Drugs GXHPC 1 (GWOXI Stem Cell Applied Technology), LPCN 1148 (Lipocine), and Belapectin (Galectin Therapeutics)

Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Cirrhosis - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights...
August 01, 2017 16:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics Reports Second Quarter 2017 Financial Results

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on the development...
June 01, 2017 09:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., June 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced the dosing of the first patients in Part Two of a...
October 05, 2015 16:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
April 30, 2015 08:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Reports Pipeline Progress and First Quarter 2015 Financial Results

Strong Enrollment in STOP-HE Trial Conference Call and Webcast at 10:00 a.m. ET PALO ALTO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage...
April 22, 2015 16:43 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics to Report Pipeline Progress and First Quarter 2015 Financial Results

PALO ALTO, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
March 11, 2015 16:01 ET | Source: Ocera Therapeutics, Inc.

Ocera Reports Fourth Quarter and Full Year 2014 Financial Results

PALO ALTO, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
September 29, 2014 09:00 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics to Present at 13th Annual BIO Investor Forum

PALO ALTO, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
July 10, 2014 08:33 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics Raises $25.2 Million in Public Offering

PALO ALTO, Calif., July 10, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) ("Ocera") today announced that it has priced an underwritten public offering of 4,200,000 shares of its common...

Next Page keyboard_arrow_right